Roland Ruckstuhl

ImVision Therapeutics, Inc. develops proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. The company was founded on January 28, 2005 and is headquartered in Hanover, Germany.

AIG South East Asia Fund Plc provided investment services. It was an investment company with variable capital authorized by European Communities Regulations, 2003. The company was founded in July, 1991 and was headquartered in Dublin, Ireland.

PineBridge Global Funds-Asia ex Japan Small Cap Equity Fund provides investment services. It invests in companies in the ''Asian Region'' countries including Hong Kong, India, Indonesia, Malaysia, Pakistan, China, Philippines, Singapore, Sri Lanka, Taiwan, and Thailand. The company was incorporated on 15th December, 1993 and is headquartered in Dublin, Ireland.

PineBridge Global Funds - Asia Balanced Fund provides investment services. It is an investment company with variable capital under the European Communities Regulations, 2003. The fund invests its total assets in a broad range of equity and equity-related securities of Asian companies. It manages and provides investors with income and long-term capital appreciation through investment in equities, equity-related securities and debt securities of Asian issuers in the Asian Region. It was incorporated on 9th June, 1997 and is located in Dublin, Ireland.

PineBridge Greater China Equity Fund provided investment services. It was an open-ended investment company with variable capital under the European Communities Regulations, 2003. It was founded in October, 2002 and was headquartered in Dublin, Ireland.

Falcon Private Bank AG (Falcon-PB) was previously known as AIG Private Bank Ltd. and was a subsidiary of New York-based American International Group, Inc. until 2009 when they were renamed Falcon upon acquisition by Aabar Investments PJSC (AD: AABAR), an investment company based in Abu Dhabi and majority-owned by the sovereign wealth fund IPIC-International Petroleum Investment Co. Established in 1965, Falcon-PB is based in Zurich with branch and representative offices in Geneva, Dubai, Abu Dhabi, Hong Kong, Singapore and London. Falcon-PB is a wholly-owned subsidiary of Aabar and provides wealth management services for an international clientele of high-net worth private individuals, family offices, asset management firms, private label partners and institutions. They offer personalized and structured private banking solutions, tailored to the individual needs of their clients.

Part of Swiss Pension & Investment Group AG, PMG Investment Solutions AG is an independent Swiss fund management company based in Zurich, Switzerland. With almost 20 years of experience, PMG provides a range of fund management services, including administration and individualized solutions for funds in Switzerland and abroad. The company was founded in 1992, and the CEO is Bernhard Schneider.

BioMedPartners AG (BMP), is an independant venture capital firm headquartered in Basel, Switzerland. BMP originated in 2002 as Seed Capital Advisors AG. The firm manages sector-focused venture capital funds including BioMedInvest, BioMedInvest II and BioMedCredit. They specialize in the biomedical sector.

The Genetics Company is a privately held drug discovery and development company active in the areas of cancer and neurodegenerative diseases. The company has identified small molecule inhibitors of two proprietary targets with in the Wnt-pathway, which is believed to play a crucial role in colon cancer. It has also identified small molecule inhibitors of BACE (beta-amyloid converting enzyme). In parallel, the company has identified and is in the process of further characterizing a series of novel growth-related drug target candidate genes for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the company currently has 29 employees. The Genetics Company offers you a range of high quality products to analyze Amyloid beta peptides x-40 and x-42 for basic research but also for pre-clinical and clinical development and in vitro diagnostics (IVD). Its CE-certified ELISA kits are the only clinically validated products for the determination of the Abeta42/40-Ratio in human CSF. These kits enable the early diagnosis of incipient Alzheimer's disease and can be used for patient stratification and monitoring in clinical trials of Alzheimer drug candidates.

SynphaBase AG provides contract research and development services to the pharmaceutical and chemical industry. Its products and services include route finding and process development, production of multi-kg up to metric tons, lab scale synthesis and carbohydrates and glycans. The firm’s catalogue includes monosaccharides as building blocks for glycan synthesis with various protecting group patterns and linker systems, disaccharides, oligosaccharides, glycosyl amino acids; core structures and building blocks for carbohydrate-based vaccine. The company was founded by in Arthur Bodenmüller in December 2000 and is headquartered in Pratteln, Switzerland.

Amgen Ltd. operates as a biotechnology firm. It engages in the research and development of human therapeutics to treat illnesses. The company was founded on March 1, 1989 and is headquartered in Cambridge, the United Kingdom.

ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA.

Creoptix AG provides biosensor devices for applications in drug discovery. It specializes in optical instruments and consumables for the label-free analysis of molecular interactions for the drug discovery. The firm’s products include instruments, sensors, and software. The company was founded by Kaspar Cottier in 2009 and is headquartered in Wadenswil, Switzerland.

Medimaps Group SA designs and provides medical tools. The company is headquartered in Plan-les-Ouates, Switzerland.

Circle Pharma, Inc. provides biotechnology services. The company was founded by Matthew P. Jacobson and Scott Lokey in June 2014 and is headquartered in San Francisco, CA.

MOMA Therapeutics, Inc. operates as a biotechnology firm. The company was founded by Dorothee Kern, Eva Nogales, Johannes Walter, and Timur Yusufzai and is headquartered in Cambridge, MA.

Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA.